Epidemiological Study of Tricuspid Regurgitation After Cardiac Transplantation. Does it Influence Survival?

Autor:	López-Vilella R; Heart Failure and Transplantation Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Department of Cardiology, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Paniagua-Martín MJ; Department of Cardiology, Complejo Hospitalario Universitario de A Coruña, Servicio Galego de Saúde (SERGAS), A Coruña, Spain., González-Vílchez F; Hospital Universitario Marqués de Valdecilla, Santander, Spain., Donoso Trenado V; Heart Failure and Transplantation Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Department of Cardiology, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Barge-Caballero E; Department of Cardiology, Complejo Hospitalario Universitario de A Coruña, Servicio Galego de Saúde (SERGAS), A Coruña, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain., Sánchez-Lázaro I; Heart Failure and Transplantation Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Department of Cardiology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain., Aller Fernández AV; Department of Intensive Medicine, Complejo Hospitalario Universitario de A Coruña, Servicio Galego de Saúde (SERGAS), A Coruña, Spain., Martínez-Dolz L; Department of Cardiology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain., Crespo-Leiro MG; Department of Cardiology, Complejo Hospitalario Universitario de A Coruña, Servicio Galego de Saúde (SERGAS), A Coruña, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.; Universidade da Coruña (UDC), A Coruña, Spain., Almenar-Bonet L; Heart Failure and Transplantation Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Department of Cardiology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.; Department of Medicine, Universidad de Valencia, Valencia, Spain.
Jazyk:	angličtina
Zdroj:	Transplant international : official journal of the European Society for Organ Transplantation [Transpl Int] 2022 Mar 21; Vol. 35, pp. 10197. Date of Electronic Publication: 2022 Mar 21 (Print Publication: 2022).
DOI:	10.3389/ti.2022.10197
Abstrakt:	Background: Tricuspid valve disease is the most frequent valvulopathy after heart transplantation (HTx). Evidence for the negative effect of post-transplant tricuspid regurgitation (TR) on survival is contradictory. The aim of this study was to analyze the causes of post-transplant TR and its effect on overall mortality. Methods: This is a retrospective observational study of all transplants performed in two Spanish centers (1009 patients) between 2000 and 2019. Of the total number of patients, 809 had no TR or mild TR and 200 had moderate or severe TR. The etiology of TR was analyzed in all cases. Results: The prevalence of moderate and severe TR was 19.8%. The risk of mortality was greater when TR was caused by early primary graft failure (PGF) or rejection ( p < 0.05). TR incidence was related to etiology: incidence of PGF-induced TR was higher in the first period, while TR due to rejection and undefined causes occurred more frequently in three periods: in the first year, in the 10-14-year period following HTx, and in the long term (16-18 years). In the multivariable analysis, TR was significantly associated with mortality/retransplantation (HR:1.04, 95% CI:1.01-1.07, p:0.02). Conclusion: The development of TR after HTx is relatively frequent. The annual incidence depends on TR severity and etiology. The risk of mortality is greater in severe TR due to PGF or rejection. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 López-Vilella, Paniagua-Martín, González-Vílchez, Donoso Trenado, Barge-Caballero, Sánchez-Lázaro, Aller Fernández, Martínez-Dolz, Crespo-Leiro and Almenar-Bonet.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu